. The Pharmacy Board of Australia is inviting feedback on its draft revised Guidelines for compounding of medicines (the draft revised guidelines). Optional questions have been provided below and you may wish to address some or all of these in your response.

Please note this survey contains the same questions as the response template (Word document). Please choose only ONE method of responding to avoid duplicating your submission.

. Please provide your details below

Name	[redacted]
Organisation name (if applicable)	Veterinary Practitioners Board - Mascot, NSW
Contact email	[redacted]

. **Published submissions will include the names (if provided) of the individuals and/or the organisations that made the submission unless confidentiality is requested.**

Do you want your responses to be published after public consultation?

- (●) Yes
- ( ) No

. **When providing feedback, please include the relevant guideline number/section that your feedback refers to.**

. The revised compounding guidelines include additional content on medicine supply pathways to consider before deciding if it is appropriate to compound a medicine (Guideline 1 When to compound medicines)

Q1. 1. Is the new content on medicine supply pathways clear and helpful? Why or why not?

Yes but content related to veterinary medicines is not appropriate.

. **When providing feedback, please include the relevant guideline number/section that your feedback refers to.**

. The compounding guidelines advise that a copy of the formula for their compounded medicine (listing all active ingredients and their strengths, and all inactive ingredients) must be provided to the patient when requested (Guideline 13 Supporting informed patient choice). Providing patients with information about the ingredients in their compounded medicine will support patient choice and safer patient outcomes.

Q2. 2. Do you agree that the formula for their compounded medicine must be provided when requested by the patient? Why or why not?

Yes. Please include client or owner of animal with patient.

. **When providing feedback, please include the relevant guideline number/section that your feedback refers to.**

. The revised compounding guidelines include content that is specific to medicines compounded for animal patients.

Q3. 3. Is the new content that is specific to medicines for animal patients clear and helpful? Why or why not?

No. Please see next response.

. **When providing feedback, please include the relevant guideline number/section that your feedback refers to.**

Q4. 4. Is there any content that needs to be changed, added or deleted in the revised guidelines? If so, please provide your suggestions and reasons.

Veterinary medicines section should mirror human medicines section where possible as veterinarians use medicines evaluated by APVMA for quality, safety and efficacy and medicines on the ARTG. The Board would be happy to assist with re-writing this section so that a section on medicines for animal use is similar to the section on medicines for human use as the same principles and consideration in the Guidance section 1.1 apply. 5.2 Quantity to be supplied for animal patients should be the same as for human patients. Quality, safety and efficacy related problems with compounded products could have a devastating impact on animal health and welfare, human health and welfare due to the impact on affected animals, and the economy in relation to performance and production animals. Supply for multiple animals in a herd of food producing species is also in breach of the Stock Medicines Act 1989 (s 39A(3)(a)). 5.4 As noted above, compounding for a food producing animal species is only possible for a single animal on the property. Definitions. There is no justification for distinguishing compounding for animal patients from compounding for human patients. Limiting preparation and supply to a ‘single issue’ as in the current guidelines is vital to protecting animal welfare.

Q5. 5. Is the language of the revised guidelines clear and is the structure helpful? Why or why not?

Yes.

Q6. 6. Please provide any other feedback about the revised guidelines.

N/A

. **When providing feedback, please include the relevant guideline number/section that your feedback refers to.**

. The Board proposes to retire the Professional practice profile for pharmacists undertaking complex compounding, as a professional practice profile should be practitioner specific, describe an individual's scope of practice and is not common to all pharmacists undertaking complex compounding. Individuals should develop their own practice profile by selecting the relevant competencies from the competency standards and customising them for use in their own practice setting.

Q7. 7. Do you agree with the Board's proposal to retire the currently published *Professional practice profile for pharmacists undertaking complex compounding*? Why or why not?

Yes.

. The Board developed the fact sheet to provide helpful context for members of the public and support their participation in this consultation.

Q8. 8. Should the Board publish the fact sheet on its website for pharmacists and members of the public to access? Why or why not?

Yes, but not with its current content.

. Thank you for your feedback. Please click on the NEXT button below to finalise your response.